World's first artificial heart implanted in US
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A patient implanted with the world's first self-contained mechanical heart was recovering yesterday after a seven-hour operation.
The procedure, carried out in Louisville, Kentucky, is the first major advance in the development of an artificial replacement heart in nearly two decades. The mechanism, which can be recharged without wires, is said to be less susceptible to infection.
The plastic and metal motorized hydraulic pump, known as the AbioCor, has been in development for 30 years and costs about $75,000 (£53,000). Yet even its developers expect the patient, who has not been identified, will only survive about 60 days – though their life expectancy was just 30 days before the transplant.
The developer, Abiomed, plans to carry out up to 15 transplants to test the functionality of the device.
John Thero, financial director of Abiomed, said: "We are starting with patients who are at the end of their lives. They are not candidates for transplant and are near death. Our goal is to provide them with a reasonable quality of life and an extension of life."
The company's President, David Lederman, said: "Every patient will probably die on the AbioCor. With this new technology, we may have failures."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments